Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free UNCY Stock Alerts

Unicycive Therapeutics (UNCY) Financials

Unicycive Therapeutics logo
$5.09 -0.12 (-2.30%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$5.08 -0.01 (-0.29%)
As of 08:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Unicycive Therapeutics

Annual Income Statements for Unicycive Therapeutics

This table shows Unicycive Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.26 -10 -18 -31 -38 -27
Consolidated Net Income / (Loss)		 -2.26 -10 -18 -31 -37 -27
Net Income / (Loss) Continuing Operations		 -2.26 -10 -18 -31 -37 -27
Total Pre-Tax Income 		-2.26 -10 -18 -31 -37 -27
Total Operating Income		 -2.02 -8.98 -18 -21 -32 -30
Total Gross Profit		 0.00 0.00 0.95 0.68 0.00 0.00
Total Revenue		 0.00 0.00 0.95 0.68 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.02 8.98 19 21 32 30
Selling, General & Admin Expense		 1.01 2.90 6.57 8.55 12 20
Research & Development Expense		 1.02 6.08 12 13 20 9.12
Total Other Income / (Expense), net		 -0.24 -1.04 -0.01 -9.77 -4.61 2.96
Interest Expense		 0.24 0.61 0.01 0.08 0.07 0.07
Interest & Investment Income		 - - 0.00 0.62 1.26 1.01
Other Income / (Expense), net		 0.00 -0.43 -0.01 -10 -5.80 2.02
Preferred Stock Dividends Declared		 - - 0.00 0.87 1.10 0.00
Basic Earnings per Share		 ($0.27) ($0.86) ($1.20) ($1.28) ($5.65) ($1.67)
Weighted Average Basic Shares Outstanding		 8.50M 11.68M 15.06M 24.54M 6.70M 15.89M
Diluted Earnings per Share		 - - - ($1.28) ($5.65) ($1.67)
Weighted Average Diluted Shares Outstanding		 - 15.00M 15.23M 24.54M 6.70M 15.89M
Weighted Average Basic & Diluted Shares Outstanding		 - 15.00M 15.23M 34.76M 119.71M 25.24M

Quarterly Income Statements for Unicycive Therapeutics

This table shows Unicycive Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.41 -7.80 -21 3.04 -4.10 -16 0.51 -6.45 -6.01 -15 -13
Consolidated Net Income / (Loss)		 -4.33 -7.80 -21 9.86 -4.10 -22 0.57 -6.45 -6.01 -15 -13
Net Income / (Loss) Continuing Operations		 -4.33 -7.80 -21 9.86 -4.10 -22 0.57 -6.45 -6.01 -15 -13
Total Pre-Tax Income 		-4.33 -7.80 -21 9.86 -4.10 -22 0.57 -6.45 -6.01 -15 -13
Total Operating Income		 -5.94 -6.31 -9.20 -7.40 -6.25 -9.26 -7.99 -6.96 -7.34 -7.22 -8.44
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.94 6.31 9.20 7.40 6.25 9.26 7.99 6.96 7.34 7.22 8.44
Selling, General & Admin Expense		 2.57 2.08 2.39 2.53 3.21 3.97 5.82 5.21 4.38 4.99 6.83
Research & Development Expense		 3.37 4.23 6.81 4.87 3.05 5.29 2.17 1.75 2.96 2.24 1.61
Total Other Income / (Expense), net		 1.61 -1.49 -12 17 2.16 -12 8.56 0.52 1.33 -7.44 -4.39
Interest Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.03 0.00
Interest & Investment Income		 0.23 0.14 0.07 0.46 0.42 0.31 0.23 0.16 0.28 0.35 0.39
Other Income / (Expense), net		 1.40 -1.61 -12 17 1.75 -13 8.35 0.37 1.07 -7.77 -4.78
Basic Earnings per Share		 ($0.13) $0.11 ($0.61) $0.80 ($0.46) $0.02 $0.04 ($0.52) ($0.33) ($0.92) ($0.54)
Weighted Average Basic Shares Outstanding		 32.63M 24.54M 34.91M 3.79M 8.89M 66.99M 11.68M 12.30M 18.07M 15.89M 23.91M
Diluted Earnings per Share		 ($0.13) - ($0.61) ($1.50) ($0.46) - ($0.50) ($0.52) ($0.33) ($0.92) ($0.54)
Weighted Average Diluted Shares Outstanding		 32.63M 24.54M 34.91M 9.41M 8.89M 66.99M 12.38M 12.30M 18.07M 15.89M 23.91M
Weighted Average Basic & Diluted Shares Outstanding		 34.75M 34.76M 37.61M 94.36M 103.80M 119.71M 120.63M 17.66M 21.49M 25.24M 26.70M

Annual Cash Flow Statements for Unicycive Therapeutics

This table details how cash moves in and out of Unicycive Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.02 17 -16 11 16 3.06
Net Cash From Operating Activities		 -1.46 -5.77 -16 -18 -29 -31
Net Cash From Continuing Operating Activities		 -1.46 -5.76 -16 -18 -29 -31
Net Income / (Loss) Continuing Operations		 -2.26 -10 -18 -31 -37 -27
Consolidated Net Income / (Loss)		 -2.26 -10 -18 -31 -37 -27
Depreciation Expense		 0.00 0.00 0.01 0.01 0.02 0.03
Amortization Expense		 0.19 0.50 0.15 - 0.41 0.54
Non-Cash Adjustments To Reconcile Net Income		 0.29 3.70 1.07 12 8.15 0.62
Changes in Operating Assets and Liabilities, net		 0.33 0.06 1.18 0.16 -0.43 -5.95
Net Cash From Investing Activities		 0.00 -0.03 -0.00 -0.01 -0.07 -12
Net Cash From Continuing Investing Activities		 0.00 -0.03 -0.00 -0.01 -0.07 -12
Purchase of Property, Plant & Equipment		 0.00 -0.03 -0.00 -0.01 -0.07 -0.02
Purchase of Investments		 - - - - 0.00 -12
Net Cash From Financing Activities		 1.44 22 -0.47 28 45 46
Net Cash From Continuing Financing Activities		 1.44 22 -0.47 30 45 46
Repayment of Debt		 -0.16 -1.36 - 0.00 -0.16 0.00
Repurchase of Preferred Equity		 - - 0.00 - -3.81 0.00
Payment of Dividends		 - - - 0.00 -1.10 0.00
Issuance of Preferred Equity		 - - 0.00 30 50 0.00
Issuance of Common Equity		 0.14 22 0.01 - 0.68 47
Other Financing Activities, net		 -0.10 0.12 -0.48 -0.50 -0.53 -0.11
Cash Interest Paid		 - - 0.01 0.02 0.01 0.00

Quarterly Cash Flow Statements for Unicycive Therapeutics

This table details how cash moves in and out of Unicycive Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.47 -2.49 39 -7.15 -5.62 -6.21 -6.37 2.56 20 -13 8.17
Net Cash From Operating Activities		 -4.42 -4.44 -6.46 -6.32 -9.25 -6.55 -8.90 -8.42 -5.96 -8.03 -6.24
Net Cash From Continuing Operating Activities		 -4.44 -4.45 -6.18 -6.32 -9.26 -6.55 -8.90 -8.41 -5.98 -8.03 -6.24
Net Income / (Loss) Continuing Operations		 -4.33 -7.80 -21 9.86 -4.10 -22 0.57 -6.45 -6.01 -15 -13
Consolidated Net Income / (Loss)		 -4.33 -7.80 -21 9.86 -4.10 -22 0.57 -6.45 -6.01 -15 -13
Depreciation Expense		 0.00 0.00 0.01 - 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 - - 0.28 -0.11 - - 0.13 - - 0.14 0.22
Non-Cash Adjustments To Reconcile Net Income		 -0.47 2.16 12 -16 -1.15 13 -7.79 0.20 -0.34 8.55 5.55
Changes in Operating Assets and Liabilities, net		 0.48 1.19 2.17 0.11 -3.86 1.83 -1.82 -2.17 -0.04 -2.06 0.81
Net Cash From Investing Activities		 - - -0.01 -0.02 -0.02 -0.02 -0.02 -0.01 -0.00 -12 -5.16
Net Cash From Continuing Investing Activities		 - - -0.01 -0.02 -0.02 -0.02 -0.02 -0.01 -0.00 -12 -5.16
Purchase of Property, Plant & Equipment		 - - -0.01 -0.02 -0.02 -0.02 -0.02 -0.01 -0.00 - -0.01
Purchase of Investments		 - - - - - - 0.00 - - - -5.15
Net Cash From Financing Activities		 -0.05 -0.21 46 -0.81 -0.16 0.37 2.55 11 26 6.61 20
Net Cash From Continuing Financing Activities		 -0.29 1.95 46 -0.60 3.45 0.36 2.55 11 26 6.61 20
Repayment of Debt		 - - - - - - -0.16 - - - 0.00
Issuance of Debt		 - - - - - - 2.79 9.83 27 - 20
Other Financing Activities, net		 - -0.21 -0.50 - - 0.52 -0.08 1.15 -0.82 -0.21 -0.61
Cash Interest Paid		 -0.04 0.02 0.01 -4.96 0.02 -0.04 0.01 0.00 - - 0.00

Annual Balance Sheets for Unicycive Therapeutics

This table presents Unicycive Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.20 19 2.82 14 32 49
Total Current Assets		 0.20 18 2.64 13 31 49
Cash & Equivalents		 0.00 17 0.46 9.70 26 29
Short-Term Investments		 - - - - 0.00 12
Prepaid Expenses		 0.00 1.83 2.19 3.70 4.81 7.69
Plant, Property, & Equipment, net		 0.00 0.03 0.02 0.03 0.08 0.07
Total Noncurrent Assets		 0.00 0.31 0.15 0.77 0.65 0.11
Other Noncurrent Operating Assets		 0.00 0.31 0.15 0.77 0.65 0.11
Total Liabilities & Shareholders' Equity		 0.20 19 2.82 14 32 49
Total Liabilities		 2.88 2.26 3.28 18 24 19
Total Current Liabilities		 2.88 2.11 3.28 18 24 19
Accounts Payable		 0.19 0.74 0.89 0.84 1.06 0.38
Accrued Expenses		 0.17 1.21 2.24 3.23 3.56 1.52
Other Current Liabilities		 0.02 0.15 0.16 13 20 17
Total Noncurrent Liabilities		 0.00 0.16 0.00 0.47 0.12 0.00
Capital Lease Obligations		 - - 0.00 - 0.12 0.00
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -2.67 16 -0.47 -3.81 7.43 30
Total Preferred & Common Equity		 -2.67 16 -0.47 -3.81 7.43 30
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -2.67 16 -0.47 -3.81 7.43 30
Common Stock		 3.25 32 34 61 109 158
Retained Earnings		 -5.92 -16 -34 -65 -101 -128
Accumulated Other Comprehensive Income / (Loss)		 - - - - 0.00 -0.00

Quarterly Balance Sheets for Unicycive Therapeutics

This table presents Unicycive Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 10 27 23 19 52 45 39 28 30 51 64
Total Current Assets		 9.96 26 22 19 52 44 38 27 30 50 64
Cash & Equivalents		 7.01 24 19 14 49 42 32 20 22 43 37
Short-Term Investments		 - - - - - - - - - - 17
Prepaid Expenses		 2.95 1.85 3.11 4.22 2.75 2.27 5.39 7.58 7.20 7.59 8.96
Plant, Property, & Equipment, net		 0.02 0.02 0.03 0.03 0.02 0.04 0.06 0.08 0.08 0.08 0.05
Total Noncurrent Assets		 0.19 1.00 0.92 0.85 0.69 0.60 0.77 0.52 0.39 0.25 0.81
Other Noncurrent Operating Assets		 0.19 1.00 0.92 0.85 0.69 0.60 0.77 0.52 0.39 0.25 0.81
Total Liabilities & Shareholders' Equity		 10 27 23 19 52 45 39 28 30 51 64
Total Liabilities		 5.55 17 16 16 31 13 11 17 14 13 27
Total Current Liabilities		 5.52 16 15 15 30 13 10 17 14 13 26
Accounts Payable		 2.29 0.79 0.50 1.08 1.24 1.47 0.55 1.40 0.78 0.96 1.14
Accrued Expenses		 3.07 1.70 1.69 2.53 3.55 3.12 2.99 4.14 2.17 2.76 3.05
Other Current Liabilities		 0.17 13 13 0.31 25 8.49 6.92 11 11 9.41 22
Total Noncurrent Liabilities		 0.03 0.72 0.63 12 0.37 0.27 0.27 0.00 0.00 0.00 0.22
Capital Lease Obligations		 0.03 - 0.63 0.55 0.37 0.27 0.27 0.00 0.00 - 0.22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4.63 -15 -19 3.43 -24 -15 28 11 16 37 38
Total Preferred & Common Equity		 4.63 -15 -19 3.39 -24 -15 28 11 16 37 38
Preferred Stock		 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4.63 -15 -19 3.39 -24 -15 28 11 16 37 38
Common Stock		 33 33 33 60 61 61 108 112 124 151 178
Retained Earnings		 -29 -49 -52 -57 -86 -76 -80 -101 -107 -113 -141
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - - - 0.01

Annual Metrics And Ratios for Unicycive Therapeutics

This table displays calculated financial ratios and metrics derived from Unicycive Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - 34,754,401.00
DEI Adjusted Shares Outstanding		 - - - - - 3,475,440.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -7.64
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -29.02% -100.00% 0.00%
EBITDA Growth		 0.00% -385.66% -100.93% -73.59% -21.98% 28.19%
EBIT Growth		 0.00% -365.74% -91.94% -72.10% -22.02% 27.49%
NOPAT Growth		 0.00% -344.41% -101.09% -15.08% -54.60% 8.10%
Net Income Growth		 0.00% -342.45% -80.27% -69.14% -20.25% 27.70%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 56.25% 70.44%
Operating Cash Flow Growth		 0.00% -295.27% -171.39% -16.82% -56.29% -9.60%
Free Cash Flow Firm Growth		 0.00% 0.00% -85.56% 83.47% -784.93% -62.00%
Invested Capital Growth		 0.00% 46.02% -869.47% -1,366.88% -38.50% 40.45%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -16.62% -9.09% -57.90% 21.49%
EBIT Q/Q Growth		 0.00% 0.00% -16.66% -9.09% -57.88% 19.89%
NOPAT Q/Q Growth		 0.00% 0.00% -16.62% -4.99% -10.11% 6.46%
Net Income Q/Q Growth		 0.00% 0.00% -16.64% -8.80% -59.68% 20.52%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.87%
Operating Cash Flow Q/Q Growth		 0.00% -17.65% -42.67% 8.25% -7.97% -4.97%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 66.60% 34.90% -33.54%
Invested Capital Q/Q Growth		 0.00% 0.00% 60.89% -30.42% -342.13% -112.31%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% -1,881.91% -4,602.67% 0.00% 0.00%
Operating Margin		 0.00% 0.00% -1,898.21% -3,077.63% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% -1,898.84% -4,604.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -1,898.84% -4,525.04% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 99.97% 100.00% 100.00% 100.00%
Interest Burden Percent		 112.08% 106.47% 100.03% 98.28% 96.86% 96.58%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 84.76% -145.04% -225.47% 1,428.96% -2,028.11% -141.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -167.50% -365.42% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -167.50% -359.15% 0.00% 0.00%
Return on Common Equity (ROCE)		 84.76% -145.04% -225.47% 1,428.96% -2,028.11% -141.14%
Return on Equity Simple (ROE_SIMPLE)		 84.76% -60.77% 3,875.11% 801.89% -494.27% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.41 -6.28 -13 -15 -22 -21
NOPAT Margin		 0.00% 0.00% -1,328.75% -2,154.34% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 34.07% -53.01% -63.66% -315.13% -79.50% -17.51%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 381.77% -302.54% -68.42%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 690.54% 1,266.22% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 1,307.68% 1,911.41% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 1,998.21% 3,177.63% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.02 -9.41 -18 -31 -38 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.83 -8.91 -18 -31 -38 -27
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.87 0.00 0.00 7.16 3.04
Price to Tangible Book Value (P/TBV)		 0.00 1.87 0.00 0.00 7.16 3.04
Price to Revenue (P/Rev)		 0.00 0.00 8.65 31.54 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 8.17 17.17 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -0.93 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.93 -1.02 -1.06 2.38 -9.90 -1.79
Leverage Ratio		 -0.08 1.37 1.35 -3.98 12.66 2.15
Compound Leverage Factor		 -0.09 1.46 1.35 -3.91 12.26 2.07
Debt to Total Capital		 -1,417.61% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -1,417.61% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 1,517.61% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.36 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -1.36 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.76 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -1.76 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -83.29 6.40 -36.47 -13.19 -6.85 -1.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.07 8.75 0.81 0.76 1.28 2.59
Quick Ratio		 0.00 7.88 0.14 0.55 1.08 2.18
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.36 -12 -1.95 -17 -28
Operating Cash Flow to CapEx		 0.00% -19,886.21% -782,550.00% -152,358.33% -39,687.50% -130,487.50%
Free Cash Flow to Firm to Interest Expense		 0.00 -10.45 -1,968.40 -23.81 -243.39 -396.96
Operating Cash Flow to Interest Expense		 -5.98 -9.47 -2,608.50 -222.96 -402.46 -441.08
Operating Cash Flow Less CapEx to Interest Expense		 -5.98 -9.52 -2,608.83 -223.11 -403.48 -441.42
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.09 0.08 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 38.04 28.13 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.18 -0.10 -0.92 -14 -19 -11
Invested Capital Turnover		 0.00 0.00 -1.87 -0.09 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.08 -0.83 -13 -5.20 7.52
Enterprise Value (EV)		 30 14 7.77 12 27 50
Market Capitalization		 28 31 8.23 21 53 92
Book Value per Share		 ($0.31) $1.10 ($0.03) ($0.11) $0.11 $1.90
Tangible Book Value per Share		 ($0.31) $1.10 ($0.03) ($0.11) $0.11 $1.90
Total Capital		 -0.18 16 -0.47 -3.81 7.43 30
Total Debt		 2.50 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 2.50 -17 -0.46 -9.70 -26 -41
Capital Expenditures (CapEx)		 0.00 0.03 0.00 0.01 0.07 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.18 -0.27 -1.10 -14 -19 -11
Debt-free Net Working Capital (DFNWC)		 -0.18 16 -0.64 -4.14 6.83 30
Net Working Capital (NWC)		 -2.67 16 -0.64 -4.14 6.83 30
Net Nonoperating Expense (NNE)		 0.85 3.73 5.42 16 14 5.89
Net Nonoperating Obligations (NNO)		 2.50 -17 -0.46 -9.70 -26 -41
Total Depreciation and Amortization (D&A)		 0.19 0.50 0.16 0.01 0.02 0.57
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -115.14% -2,049.78% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% -67.30% -612.59% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% -67.30% -612.59% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.86) ($1.20) ($1.28) ($0.56) ($1.67)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 11.68M 15.06M 24.54M 66.99M 15.89M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.56) ($1.67)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 15.00M 15.23M 34.76M 66.99M 15.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 15.00M 15.23M 34.76M 119.71M 25.24M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.41 -6.28 -13 -15 -22 -21
Normalized NOPAT Margin		 0.00% 0.00% -1,328.75% -2,154.34% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -1,899.47% -4,525.04% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -8.28 -15.45 -3,009.67 -378.99 -534.07 -387.27
NOPAT to Interest Expense		 -5.80 -10.32 -2,106.07 -177.34 -316.65 -291.01
EBIT Less CapEx to Interest Expense		 -8.28 -15.50 -3,010.00 -379.13 -535.08 -387.61
NOPAT Less CapEx to Interest Expense		 -5.80 -10.37 -2,106.40 -177.49 -317.66 -291.35
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.98% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.98% 0.00%

Quarterly Metrics And Ratios for Unicycive Therapeutics

This table displays calculated financial ratios and metrics derived from Unicycive Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - 34,754,401.00 34,754,401.00 34,754,401.00 34,754,401.00
DEI Adjusted Shares Outstanding		 - - - - - - - 3,475,440.00 3,475,440.00 3,475,440.00 3,475,440.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -1.86 -1.73 -4.20 -3.69
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 17.71% -49.74% -42.64% 334.63% 1.08% -175.58% 101.77% -170.82% -39.50% 31.96% -2,730.36%
EBIT Growth		 18.27% -48.61% -44.14% 332.90% 0.99% -175.56% 101.71% -170.03% -39.54% 31.29% -3,781.62%
NOPAT Growth		 -6.91% -18.54% -119.04% -144.63% -5.27% -46.72% -24.00% 34.14% -17.45% 22.01% 26.07%
Net Income Growth		 22.03% -46.36% -43.83% 356.77% 5.47% -176.03% 102.72% -165.42% -46.75% 31.86% -2,349.65%
EPS Growth		 0.00% 0.00% 0.00% 48.28% 61.54% 0.00% 91.80% 65.33% 28.26% 60.52% -8.00%
Operating Cash Flow Growth		 -24.11% 27.04% -64.69% -14.85% -109.23% -47.51% -37.90% -33.25% 35.56% -22.66% 29.90%
Free Cash Flow Firm Growth		 966.92% 381.60% -39.40% -211.03% -372.98% -115.69% -510.46% -6.39% 60.43% -799.27% 108.66%
Invested Capital Growth		 -339.87% -1,366.88% -92.68% 10.48% 59.15% -38.50% 68.08% 41.97% -23.23% 40.45% -96.11%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -14.59% -74.34% -161.88% 144.85% -148.31% -385.68% 101.68% -1,893.73% 4.83% -136.87% 12.44%
EBIT Q/Q Growth		 -12.43% -74.33% -165.37% 144.78% -147.79% -385.19% 101.65% -1,935.38% 4.77% -138.90% 11.83%
NOPAT Q/Q Growth		 -37.39% -6.30% -45.82% -14.87% 40.88% -48.15% -23.24% 38.99% -5.44% 1.62% -16.81%
Net Income Q/Q Growth		 -12.90% -79.97% -168.83% 147.01% -141.56% -425.51% 102.65% -1,231.05% 6.76% -144.00% 12.57%
EPS Q/Q Growth		 55.17% 0.00% 0.00% 0.00% 66.67% 0.00% 0.00% -940.00% 36.54% -178.79% 41.30%
Operating Cash Flow Q/Q Growth		 19.63% -0.38% -45.44% 2.12% -46.42% 29.23% -35.97% 5.43% 29.19% -34.72% 22.30%
Free Cash Flow Firm Q/Q Growth		 -50.28% 112.37% -22.15% -235.05% -22.25% 87.80% -1,937.14% 64.99% 54.53% -202.62% 117.98%
Invested Capital Q/Q Growth		 8.76% -30.42% -97.03% 61.82% 58.36% -342.13% 54.58% 30.60% 11.58% -112.31% -50.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.40% 98.48% 99.77% 104.74% 91.08% 98.65% 158.77% 97.84% 95.79% 97.84% 97.02%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -696.63% 1,428.96% -229.05% -121.76% -147.05% -2,028.11% -92.09% -131.87% -102.29% -141.14% -163.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -692.82% 1,428.96% 280.83% 109.15% -146.85% -2,028.11% 36.79% -4.37% -102.29% -141.14% -163.14%
Return on Equity Simple (ROE_SIMPLE)		 -828.14% 0.00% 151.01% 156.53% -82.59% 0.00% -134.82% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.16 -4.42 -6.44 -7.40 -4.38 -6.48 -7.99 -4.87 -5.14 -5.06 -5.91
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.70% -66.55% -39.96% 57.82% 1.22% -83.93% 25.13% -4.93% -2.33% -28.56% -18.66%
Return On Investment Capital (ROIC_SIMPLE)		 - 116.00% 26.75% - - -87.24% -70.88% -29.67% -13.71% -16.74% -15.57%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.54 -7.92 -21 9.41 -4.50 -22 0.36 -6.59 -6.28 -15 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.54 -7.92 -21 9.30 -4.49 -22 0.37 -6.58 -6.27 -15 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.28 0.00 0.00 0.00 1.30 7.16 6.32 3.57 2.10 3.04 4.17
Price to Tangible Book Value (P/TBV)		 8.28 0.00 0.00 0.00 1.30 7.16 6.32 3.57 2.10 3.04 4.17
Price to Revenue (P/Rev)		 41.58 31.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 21.21 17.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.16 0.00 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01
Long-Term Debt to Equity		 0.16 0.00 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01
Financial Leverage		 -2.58 2.38 -2.25 -1.56 -1.47 -9.90 -2.06 -1.34 -1.14 -1.79 -1.51
Leverage Ratio		 3.67 -3.98 2.47 1.77 1.85 12.66 2.43 1.56 1.37 2.15 1.89
Compound Leverage Factor		 3.51 -3.92 2.46 1.85 1.69 12.49 3.86 1.53 1.31 2.10 1.83
Debt to Total Capital		 13.85% 0.00% 1.68% 0.87% 0.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.57%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 13.85% 0.00% 1.68% 0.87% 0.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.57%
Preferred Equity to Total Capital		 1.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 208.96% 146.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 85.05% 100.00% -110.65% -46.96% 99.06% 100.00% 100.00% 100.00% 100.00% 100.00% 99.43%
Debt to EBITDA		 -0.02 0.00 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to EBITDA		 0.48 0.00 1.30 1.75 1.34 0.00 0.00 0.00 0.00 0.00 1.35
Long-Term Debt to EBITDA		 -0.02 0.00 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01
Debt to NOPAT		 -0.04 0.00 -0.02 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to NOPAT		 1.00 0.00 2.69 2.05 1.57 0.00 0.00 0.00 0.00 0.00 2.59
Long-Term Debt to NOPAT		 -0.04 0.00 -0.02 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01
Altman Z-Score		 -3.58 -7.80 -2.18 1.27 -0.40 -5.18 -1.98 -2.49 0.94 -1.01 0.49
Noncontrolling Interest Sharing Ratio		 0.55% 0.00% 222.61% 189.64% 0.14% 0.00% 139.95% 96.69% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.20 0.76 1.71 3.37 3.61 1.28 1.64 2.18 3.83 2.59 2.40
Quick Ratio		 0.93 0.55 1.62 3.19 3.09 1.08 1.19 1.65 3.25 2.18 2.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3.85 8.17 6.36 -8.59 -11 -1.28 -26 -9.14 -4.16 -13 2.26
Operating Cash Flow to CapEx		 0.00% 0.00% -107,600.00% -31,595.00% -38,550.00% -29,763.64% -55,643.75% -140,333.33% -298,100.00% 0.00% -78,012.50%
Free Cash Flow to Firm to Interest Expense		 213.74 408.53 318.06 -536.94 -700.18 -64.09 -1,740.67 -703.08 -277.09 -449.22 0.00
Operating Cash Flow to Interest Expense		 -245.67 -221.95 -322.80 -394.94 -616.80 -327.40 -593.53 -647.69 -397.47 -286.86 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -245.67 -221.95 -323.10 -396.19 -618.40 -328.50 -594.60 -648.15 -397.60 -286.86 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 25.96 28.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -10 -14 -27 -10 -4.23 -19 -8.50 -5.90 -5.22 -11 -17
Invested Capital Turnover		 -0.11 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -8.00 -13 -13 1.19 6.13 -5.20 18 4.27 -0.98 7.52 -8.17
Enterprise Value (EV)		 14 12 46 52 4.20 27 51 36 36 50 103
Market Capitalization		 28 21 48 47 36 53 71 59 79 92 157
Book Value per Share		 $0.10 ($0.11) ($0.70) ($0.39) $0.31 $0.11 $0.10 $1.34 $2.07 $1.90 $1.58
Tangible Book Value per Share		 $0.10 ($0.11) ($0.70) ($0.39) $0.31 $0.11 $0.10 $1.34 $2.07 $1.90 $1.58
Total Capital		 3.99 -3.81 22 32 28 7.43 11 16 37 30 38
Total Debt		 0.55 0.00 0.37 0.27 0.27 0.00 0.00 0.00 0.00 0.00 0.22
Total Long-Term Debt		 0.55 0.00 0.37 0.27 0.27 0.00 0.00 0.00 0.00 0.00 0.22
Net Debt		 -14 -9.70 -49 -42 -32 -26 -20 -22 -43 -41 -54
Capital Expenditures (CapEx)		 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.01 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -14 -28 -11 -5.07 -19 -9.10 -6.37 -5.54 -11 -18
Debt-free Net Working Capital (DFNWC)		 3.11 -4.14 21 31 27 6.83 11 16 37 30 37
Net Working Capital (NWC)		 3.11 -4.14 21 31 27 6.83 11 16 37 30 37
Net Nonoperating Expense (NNE)		 0.18 3.38 15 -17 -0.28 15 -8.56 1.57 0.87 9.61 6.92
Net Nonoperating Obligations (NNO)		 -14 -9.70 -48 -42 -32 -26 -20 -22 -43 -41 -54
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.28 -0.11 0.01 0.01 0.01 0.01 0.01 0.15 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 -1,664.00% -2,049.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 461.19% -612.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 461.19% -612.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.13) $0.11 ($0.61) $0.08 ($0.05) $0.02 $0.00 ($0.52) ($0.33) ($0.92) ($0.54)
Adjusted Weighted Average Basic Shares Outstanding		 32.63M 24.54M 34.91M 37.91M 88.94M 66.99M 116.82M 12.30M 18.07M 15.89M 23.91M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.15) ($0.05) $0.00 ($0.05) ($0.52) ($0.33) ($0.92) ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 34.75M 24.54M 37.61M 94.05M 88.94M 66.99M 123.83M 12.30M 18.07M 15.89M 23.91M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.92) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 34.75M 34.76M 37.61M 94.36M 103.80M 119.71M 120.63M 17.66M 21.49M 25.24M 26.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.16 -4.42 -6.44 -5.18 -4.38 -6.48 -5.59 -4.87 -5.14 -5.06 -5.91
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -252.33 -395.90 -1,050.60 588.06 -299.80 -1,090.95 23.93 -506.85 -418.33 -535.39 0.00
NOPAT to Interest Expense		 -230.92 -220.92 -322.14 -462.56 -291.71 -324.14 -532.60 -374.93 -342.63 -180.58 0.00
EBIT Less CapEx to Interest Expense		 -252.33 -395.90 -1,050.90 586.81 -301.40 -1,092.05 22.87 -507.31 -418.47 -535.39 0.00
NOPAT Less CapEx to Interest Expense		 -230.92 -220.92 -322.44 -463.81 -293.31 -325.24 -533.67 -375.39 -342.76 -180.58 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -2.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -2.98% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Unicycive Therapeutics’ latest quarterly results show a company still in development-stage mode, with no revenue, sizable operating losses, and ongoing reliance on external financing. The most recent quarter, Q1 2026, was better than the prior quarter on several fronts: operating expenses fell, net loss narrowed, and the balance sheet ended with a much larger cash position. Still, the business continues to burn cash and remains dependent on debt and other financing sources to fund operations.

  • Cash improved materially in Q1 2026. Cash and equivalents rose to $37.4 million from $26.7 million at the end of Q4 2025, supported by financing activity and a positive net change in cash.
  • Total liquidity is stronger when short-term investments are included. Cash plus short-term investments totaled about $54.6 million at Q1 2026.
  • Quarterly operating loss improved. Operating expenses fell to $8.4 million in Q1 2026 from $7.2 million in Q4 2025? Actually, on a cleaner comparison to the prior quarter’s reported figures, the company still posted an operating loss, but the net loss improved to $12.8 million from $14.7 million.
  • R&D spending declined sharply. Research and development expense dropped to $1.6 million in Q1 2026 from $2.2 million in Q4 2025, which may indicate tighter spending discipline or a shift in development timing.
  • Net loss per share improved. Basic EPS was -$0.54 in Q1 2026 versus -$0.92 in Q4 2025.
  • The company remains pre-revenue. Unicycive recorded no revenue in every quarter shown, so the investment case still depends on future product progress rather than current sales.
  • Interest and other income helped partially offset operating losses in some periods. However, those gains have been inconsistent and are not enough to change the underlying cash-burn profile.
  • Operating cash flow is still negative. Q1 2026 operating cash flow was -$6.2 million, showing the core business continues to consume cash.
  • Financing remains a necessity. The company raised $20.2 million of debt in Q1 2026, highlighting continued dependence on outside capital.
  • Retained earnings are deeply negative. Retained earnings stood at -$140.6 million at Q1 2026, reflecting years of accumulated losses.

Longer-term trend: Compared with 2024 and early 2025, Unicycive has improved its balance sheet and reduced near-term cash pressure, but the broader picture remains challenging. Revenue has been absent for at least the last four years in the data provided, while quarterly losses have generally remained in the mid-single-digit millions to low double-digit millions. The company’s cash balance has swung significantly over time because of periodic financing, not operating profitability.

Bottom line: Unicycive Therapeutics appears to be in a “fund the pipeline and preserve cash” phase. The latest quarter brought some progress on cost control and liquidity, but investors should still view the stock as highly speculative until the company shows meaningful clinical, regulatory, or commercial traction.

07/14/26 08:09 AM ETAI Generated. May Contain Errors.

Unicycive Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Unicycive Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Unicycive Therapeutics' net income appears to be on an upward trend, with a most recent value of -$26.56 million in 2025, rising from -$2.26 million in 2020. The previous period was -$36.73 million in 2024. See Unicycive Therapeutics' forecast for analyst expectations on what's next for the company.

Unicycive Therapeutics' total operating income in 2025 was -$29.52 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $29.52 million

Over the last 5 years, Unicycive Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Unicycive Therapeutics' total liabilities were at $18.94 million at the end of 2025, a 21.9% decrease from 2024, and a 558.7% increase since 2020.

In the past 5 years, Unicycive Therapeutics' cash and equivalents has ranged from $0.00 in 2020 to $29.20 million in 2025, and is currently $29.20 million as of their latest financial filing in 2025.

Over the last 5 years, Unicycive Therapeutics' book value per share changed from -0.31 in 2020 to 1.90 in 2025, a change of -705.0%.


Related Companies

Financial statements for NASDAQ:UNCY last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
BNZI Lands a Zacks Upgrade!
Banzai International (NASDAQ: BNZI) just received a Zacks Rank 2 (Buy) upgrade, driven by improving earnings e...
Huge Alerts | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Under $1 while the market panics
The new deadline for crypto’s best bill, the Clarity Act, is August 7th. That's the Senate's final session day...
Crypto 101 Media | Sponsoredtc pixel